GRUPO ESPANOL DE INVESTIGACION EN CANCER DE PULMON

Their core work

GECP SLCG (Grupo Español de Investigación en Cáncer de Pulmón) is a Spanish clinical oncology research association based in Barcelona, specializing in lung cancer and related malignancies. Their core value to EU research consortia is access to clinical expertise, oncologist networks, and real-world patient cohort data across lung cancer, breast cancer, and lymphoma populations. In H2020 projects, they have contributed domain knowledge and clinical validation capacity to AI and big data platforms aimed at improving precision medicine and long-term follow-up for cancer survivors. They operate as a specialist clinical partner rather than a technology developer — bridging research software and clinical reality.

What they specialise in

How they've shifted over time

GECP's first H2020 engagement (IASIS, 2017) involved broad heterogeneous data integration for precision medicine — a wide-scope digital health initiative with no single cancer focus recorded in keywords. By their second project (CLARIFY, 2020), the focus sharpened considerably: AI-powered long-term follow-up specifically for cancer survivors across lung, breast, and lymphoma cohorts. This shift suggests the organization is moving from general participation in health data platforms toward specialized clinical AI projects where their oncology patient network is a direct asset.

GECP is moving toward AI-driven survivorship care tools — a growing clinical need — making them a relevant partner for any consortium tackling long-term cancer monitoring, patient-reported outcomes, or oncology digital health platforms.

How they like to work

GECP has exclusively participated as a consortium member across both H2020 projects and has never taken on a coordinator role, pointing to a deliberate focus on clinical contribution rather than project management. With 20 unique partners across 7 countries from just 2 projects, they work in mid-to-large international consortia. This suggests they are sought out for their clinical network and patient cohort access, not for technical leadership.

GECP has collaborated with 20 unique partners across 7 countries through 2 projects — an unusually broad network for such a small EU project portfolio, indicating they join well-connected large consortia. Their partnerships appear distributed across European countries rather than concentrated in Spain.

What sets them apart

GECP is one of Spain's leading lung cancer clinical research associations, giving them direct access to oncologist communities and lung cancer patient cohorts that technology-focused partners cannot replicate. For any AI, digital health, or precision medicine consortium that needs real-world clinical grounding in oncology — particularly lung cancer or survivorship — GECP provides the clinical credibility and data access that turns a research prototype into a validated tool. Their association structure (VAT prefix G) also means they can mobilize clinical networks across multiple Spanish hospitals and research centers.

Highlights from their portfolio

• CLARIFY
  Largest budget (€295,000) and the clearest expression of GECP's niche — AI-powered follow-up for cancer long survivors across lung, breast, and lymphoma — directly aligning with the survivorship care gap in European oncology.
• IASIS
  Earlier project demonstrating GECP's ability to integrate into large-scale precision medicine data platforms, establishing their EU consortium track record before their more specialized survivorship focus.